Centrexion Therapeutics competitors

Dr. Walker is President and Chief Executive Officer at Aclaris Therapeutics. He is also a co-founding partner of NeXeption, LLC, a biopharmaceutical management company. He is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the biopharmaceutical industry. Prior to founding Aclaris, he was co-founder, President and CEO of Vicept Therapeutics (acquired by Allergan). Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories); Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb. He began his pharmaceutical industry career at Johnson and Johnson. Dr. Walker co-founded and is Vice Chairman of Alexar Therapeutics, Inc. and serves on the Board of Directors of Sebacia, Inc. He also co-founded and serves on the Board of Directors of the Dermatology Summit, an Advancing Innovation in Dermatology Conference. He previously served on the Board of Directors for Octagon and the Advisory Board of Flexible Medical Systems. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania.

Mike Raab has been Chief Executive Officer and Chairman of Ardelyx since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA) one of the world’s largest and most successful venture capital firms and specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation. He built the Latin American division for Genzyme and was also Senior Product Manager for Genzyme’s $1+ billion therapies for Gaucher Disease, Ceredase and Cerezyme, and was instrumental in the worldwide launch of both products. Mike also spent two years with Genzyme’s Diagnostic products and services division. Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers. Mike received his B.A. from DePauw University.

J. David Hansen is a President & Chief Executive Officer at MABVAX THERAPEUTICS HOLDINGS, INC. and Board Member at MABVAX THERAPEUTICS HOLDINGS, INC..

Mr. Stephen Zaruby W. is a President and Chief Executive Officer at AURINIA PHARMACEUTICALS INC and is based in United States.